Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study

Kubackova Katerina; Melichar Bohuslav; Bortlicek Zbynek; Pavlik Tomas; Poprach Alexandr; Svoboda Marek; Lakomy Radek; Vyzula Rostislav; Kiss Igor; Dusek Ladislav; Prausova Jana; Buchler Tomas

首页> 外文期刊>Targeted oncology >Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study

【24h】

Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study

机译：舒尼替尼治疗转移性肾癌患者的两种预后模型比较：一项基于注册表的回顾性研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The study aimed to compare two prognostic models in terms of progression-free survival (PFS), median overall survival (OS), and 1-year survival in patients treated first-line with sunitinib for metastatic renal cell carcinoma (mRCC).

机译：该研究旨在比较一线舒尼替尼治疗转移性肾细胞癌（mRCC）患者的无进展生存期（PFS），中位总体生存期（OS）和1年生存期的两种预后模型。

著录项

来源
《Targeted oncology》 |2015年第4期|共7页
作者
Kubackova Katerina; Melichar Bohuslav; Bortlicek Zbynek; Pavlik Tomas; Poprach Alexandr; Svoboda Marek; Lakomy Radek; Vyzula Rostislav; Kiss Igor; Dusek Ladislav; Prausova Jana; Buchler Tomas;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study [J] . Kubackova Katerina, Melichar Bohuslav, Bortlicek Zbynek, Targeted oncology . 2015,第4期

机译：舒尼替尼治疗转移性肾癌患者的两种预后模型比较：一项基于注册表的回顾性研究
2. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib [J] . YuasaT., TsuchiyaN., UrakamiS., BJU international . 2012,第9期

机译：舒尼替尼治疗日本转移性肾细胞癌患者整体生存的临床疗效和预后因素
3. Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model [J] . Aristotelis Bamias, Alexandra Karadimou, Sofia Lampaki, BMC Cancer . 2010,第1期

机译：舒尼替尼治疗晚期肾细胞癌的预后分层：与纪念斯隆-凯特琳预后因素模型的比较
4. When to Treat Metastatic Renal Cell Carcinoma Comorbidities, Systemic Therapy, and Active Surveillance in Metastatic Kidney Cancer [C] . Brian I. Rini Genitourinary Cancers Symposium . 2012

机译：何时治疗转移性肾细胞癌的组合，全身治疗，以及在转移性肾癌中的活跃监测
5. Retrospective analysis of treatment-related risk of secondary malignancies among patients diagnosed and treated for childhood cancers at Cook Children's Medical Center [D] . Le, Phuong. 2011

机译：在库克儿童医学中心诊断和治疗儿童癌症的患者中与治疗相关的继发性恶性肿瘤风险的回顾性分析
6. Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients [O] . Çetin Ordu, Kezban N. Pilanci, Nilüfer Avcı, 2016

机译：转移性肾细胞癌患者中舒尼替尼毒性的预后相关性和连续与间歇性舒尼替尼给药方案的比较
7. Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients [O] . Çetin Ordu, Kezban N. Pilanci, Nilüfer Avcı, 2016

机译：舒尼替尼毒性的预后相关性以及转移性肾细胞癌患者中连续与间歇性舒尼替尼给药方案的比较

Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study

摘要

著录项

相似文献

相关主题

期刊订阅